Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: LVR013
MIFTS: 75

Liver Disease

Categories: Blood diseases, Endocrine diseases, Gastrointestinal diseases, Genetic diseases, Liver diseases, Metabolic diseases, Nephrological diseases, Rare diseases
Genes Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Liver Disease

About this section

MalaCards integrated aliases for Liver Disease:

Name: Liver Disease 38 12 15
Liver Diseases 55 43 44 73
Liver Dysfunction 55 73
Liver Failure 55 73
Abnormality of the Liver 29
Disorder of Liver 12
Hepatic Disorder 12
Hepatic Failure 29
Hepatic Disease 15

Classifications:

MalaCards categories:
Global: Metabolic diseases Genetic diseases Rare diseases
Anatomical: Gastrointestinal diseases Endocrine diseases Liver diseases Nephrological diseases Blood diseases
See all MalaCards categories (disease lists)
ICD10: 33


External Ids:

Disease Ontology 12 DOID:409
ICD9CM 35 573.9
MeSH 44 D008107
NCIt 50 C3196
SNOMED-CT 68 62857009
Sources

Summaries for Liver Disease

About this section
MedlinePlus : 43 Your liver is the largest organ inside your body. It helps your body digest food, store energy, and remove poisons. There are many kinds of liver diseases: Diseases caused by viruses, such as hepatitis A, hepatitis B, and hepatitis C Diseases caused by drugs, poisons, or too much alcohol. Examples include fatty liver disease and cirrhosis. Liver cancer Inherited diseases, such as hemochromatosis and Wilson disease Symptoms of liver disease can vary, but they often include swelling of the abdomen and legs, bruising easily, changes in the color of your stool and urine, and jaundice, or yellowing of the skin and eyes. Sometimes there are no symptoms. Tests such as imaging tests and liver function tests can check for liver damage and help to diagnose liver diseases.

MalaCards based summary : Liver Disease, also known as liver diseases, is related to fatty liver disease and polycystic liver disease, and has symptoms including nausea and vomiting, constipation and abdominal pain. An important gene associated with Liver Disease is MEG3 (Maternally Expressed 3), and among its related pathways/superpathways are Metabolism and Selenium Micronutrient Network. The drugs Tocopherol and Amlodipine have been mentioned in the context of this disorder. Affiliated tissues include liver, testes and kidney, and related phenotypes are homeostasis/metabolism and growth/size/body region

Wikipedia : 76 Liver disease (also called hepatic disease) is a type of damage to or disease of the... more...

Sources

Related Diseases for Liver Disease

About this section

Diseases in the Liver Disease family:

Liver Failure, Infantile, Transient Infantile Liver Failure Syndrome 1
Infantile Liver Failure Syndrome 2 Acute Liver Failure

Diseases related to Liver Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 994)
# Related Disease Score Top Affiliating Genes
1 fatty liver disease 34.5 ADIPOQ CYP2E1 INS PNPLA3 TNF
2 polycystic liver disease 34.3 ALB GANAB PKD1 PKHD1 PRKCSH
3 polycystic liver disease 1 with or without kidney cysts 34.3 PKD1 PKHD1 PRKCSH
4 nonalcoholic fatty liver disease 34.2 ADIPOQ CYP2E1 INS KRT18 PNPLA3 TNF
5 fatty liver disease, nonalcoholic 1 34.1 ADIPOQ GPT INS KRT18
6 polycystic kidney disease 4 with or without polycystic liver disease 34.0 PKD1 PKHD1 PRKCSH
7 polycystic kidney disease 2 with or without polycystic liver disease 34.0 GANAB PKD1 PKHD1 PRKCSH
8 polycystic kidney disease 1 with or without polycystic liver disease 34.0 PKD1 PKHD1 PRKCSH
9 alcoholic hepatitis 33.2 ALB CYP2E1 F2 GPT KRT18 TNF
10 nonalcoholic steatohepatitis 33.1 ADIPOQ CYP2E1 F2 GPT INS KRT18
11 wilson disease 32.4 ALB F2 GPT
12 cholangitis, primary sclerosing 32.2 ABCB4 ALB DLAT GPT
13 acute liver failure 32.1 ALB F2 GPT
14 hepatic encephalopathy 32.1 ALB F2 GPT TNF
15 sclerosing cholangitis 32.0 ABCB11 ABCB4 ALB TNF
16 congenital hepatic fibrosis 31.9 PKD1 PKHD1
17 cryptogenic cirrhosis 31.7 F2 KRT18
18 caroli disease 31.7 PKD1 PKHD1
19 hepatitis 31.7 F2 GPT KRT18 TNF
20 bile duct disease 31.6 ABCB11 ABCB4 ALB F2 GPT
21 autoimmune hepatitis 31.5 DLAT F2 GPT
22 cholestasis, progressive familial intrahepatic, 4 31.4 ABCB11 ABCB4
23 alcoholic liver cirrhosis 31.3 ALB CYP2E1 F2 PNPLA3
24 hepatitis b 31.3 ALB F2 GPT TNF
25 portal hypertension 30.9 ALB F2 GPT PKHD1 TNF
26 hepatic coma 30.8 ALB F2 GPT
27 diabetes mellitus, noninsulin-dependent 30.8 ADIPOQ ALB GPT INS TNF
28 kidney disease 30.8 ADIPOQ ALB GANAB INS PKD1 PKHD1
29 infantile liver failure syndrome 1 30.7 ALB F2 FAH GPT
30 viral hepatitis 30.7 ALB F2 GPT KRT18 SERPINA1 TNF
31 polycystic kidney disease 30.7 GANAB PKD1 PKHD1 PRKCSH
32 cholestasis 30.7 ABCB11 ABCB4 F2 GPT HSD3B7
33 sleep apnea 30.6 ADIPOQ INS TNF
34 primary biliary cirrhosis 30.6 ABCB4 ALB DLAT F2
35 liver cirrhosis 30.5 ADIPOQ ALB CYP2E1 F2 GPT KRT18
36 cholangitis 30.5 ABCB11 ABCB4 ALB DLAT F2 GPT
37 arteries, anomalies of 30.5 ADIPOQ ALB INS TNF
38 chronic kidney failure 30.5 ADIPOQ ALB INS PKD1
39 peritonitis 30.5 ALB F2 TNF
40 hepatitis a 30.4 ALB F2 GPT TNF
41 body mass index quantitative trait locus 11 30.4 ADIPOQ CYP2E1 GPT INS PNPLA3 TNF
42 autosomal dominant polycystic kidney disease 30.4 ALB GANAB PKD1 PKHD1
43 cholelithiasis 30.3 ABCB4 ALB GPT
44 obstructive jaundice 30.3 ALB F2 GPT TNF
45 dengue hemorrhagic fever 30.3 ALB F2 TNF
46 atherosclerosis susceptibility 30.3 ADIPOQ INS TNF
47 hepatitis e 30.3 ALB F2 GPT TNF
48 bilirubin metabolic disorder 30.2 ALB F2 GPT
49 hypertension, essential 30.2 ADIPOQ ALB INS PKD1
50 hemorrhagic fever 30.2 ALB F2 GPT TNF

Comorbidity relations with Liver Disease via Phenotypic Disease Network (PDN):


Active Peptic Ulcer Disease Acute Cystitis
Acute Pancreatitis Deficiency Anemia
Familial Atrial Fibrillation Heart Disease
Hepatic Encephalopathy Ischemic Heart Disease
Protein-Energy Malnutrition

Graphical network of the top 20 diseases related to Liver Disease:



Diseases related to Liver Disease
Sources

Symptoms & Phenotypes for Liver Disease

About this section

UMLS symptoms related to Liver Disease:


nausea and vomiting, constipation, abdominal pain, diarrhea, hepatosplenomegaly, icterus, dyspepsia, heartburn, gastrointestinal gas, digestive system symptom, liver tender, abnormal bruising

MGI Mouse Phenotypes related to Liver Disease:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.13 ABCB11 ABCB4 ADIPOQ ALB CYP2E1 F2
2 growth/size/body region MP:0005378 10.11 ABCB11 ABCB4 ADIPOQ F2 FAH HSD3B7
3 liver/biliary system MP:0005370 10.1 ABCB11 ABCB4 ADIPOQ ALB CYP2E1 FAH
4 digestive/alimentary MP:0005381 10.01 ABCB4 ALB F2 HSD3B7 INS PKD1
5 mortality/aging MP:0010768 9.97 ABCB11 ADIPOQ ALB CYP2E1 F2 FAH
6 neoplasm MP:0002006 9.5 ABCB4 ADIPOQ ALB CYP2E1 FAH PKD1
7 renal/urinary system MP:0005367 9.17 ADIPOQ ALB FAH INS PKD1 PKHD1
Sources

Drugs & Therapeutics for Liver Disease

About this section

Drugs for Liver Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 1339)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Tocopherol Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 1406-66-2 14986
2
Amlodipine Approved Phase 4,Phase 1 88150-42-9 2162
3
Telmisartan Approved, Investigational Phase 4 144701-48-4 65999
4
Perindopril Approved Phase 4 107133-36-8, 82834-16-0 107807
5
Angiotensin II Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 11128-99-7, 68521-88-0, 4474-91-3 172198 65143
6
Insulin Glargine Approved Phase 4,Phase 2 160337-95-1
7
Zinc Approved, Investigational Phase 4,Phase 2,Phase 3,Not Applicable 7440-66-6
8
Exenatide Approved, Investigational Phase 4,Phase 2,Phase 3 141758-74-9 15991534
9
Ursodeoxycholic acid Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 128-13-2 31401
10
Lamivudine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 134678-17-4 60825
11
Entecavir Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 142217-69-4 153941
12
Ethanol Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 64-17-5 702
13
Metformin Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 657-24-9 14219 4091
14 Orange Approved Phase 4,Phase 2,Not Applicable
15
Morphine Approved, Investigational Phase 4,Phase 3,Phase 1,Not Applicable 57-27-2 5288826
16
Emtricitabine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 143491-57-0 60877
17
Adefovir Dipivoxil Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 142340-99-6 60871
18
Gabapentin Approved, Investigational Phase 4,Phase 3,Not Applicable 60142-96-3 3446
19
gamma-Aminobutyric acid Approved, Investigational Phase 4,Phase 3,Not Applicable 56-12-2 119
20
glycyrrhizin Approved, Experimental Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 1405-86-3 3495
21
Lenograstim Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 135968-09-1
22
Alprostadil Approved, Investigational Phase 4,Phase 2,Phase 1 745-65-3 149351 5280723
23
Tacrolimus Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 104987-11-3 445643 439492
24
Ezetimibe Approved Phase 4,Phase 2,Phase 1 163222-33-1 150311
25
Magnesium oxide Approved Phase 4 1309-48-4 14792
26
Peginterferon alfa-2a Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 198153-51-4 5360545
27
Ribavirin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 36791-04-5 37542
28
Insulin glulisine Approved Phase 4 207748-29-6
29
Lactulose Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 4618-18-2 11333
30
Liraglutide Approved Phase 4,Phase 3,Phase 2 204656-20-2 44147092
31
Telbivudine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 3424-98-4 159269
32 tannic acid Approved Phase 4,Phase 3,Phase 2,Not Applicable
33
Benzocaine Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 94-09-7, 1994-09-7 2337
34
Nitazoxanide Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 55981-09-4 41684
35
Acamprosate Approved, Investigational Phase 4 77337-76-9 71158
36
Rifaximin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 80621-81-4 6436173
37
Erythromycin Approved, Investigational, Vet_approved Phase 4,Phase 1,Not Applicable 114-07-8 12560
38
Simvastatin Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 79902-63-9 54454
39
Peginterferon alfa-2b Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 99210-65-8, 215647-85-1
40
Milk thistle Approved, Experimental, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 65666-07-1
41
Mycophenolic acid Approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 24280-93-1 446541
42
Propranolol Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 525-66-6 4946
43
Nadolol Approved Phase 4,Phase 3 42200-33-9 39147
44
Carvedilol Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 72956-09-3 2585
45
Spironolactone Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 52-01-7, 1952-01-7 5833
46
Ritonavir Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 155213-67-5 392622
47
Losartan Approved Phase 4,Phase 3,Phase 2,Phase 1 114798-26-4 3961
48
Cefotaxime Approved Phase 4 63527-52-6 456256 5742673
49
Ciprofloxacin Approved, Investigational Phase 4,Phase 1,Early Phase 1,Not Applicable 85721-33-1 2764
50
Amoxicillin Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 26787-78-0 33613

Interventional clinical trials:

(show top 50) (show all 8488)
# Name Status NCT ID Phase Drugs
1 Prospective Validation of a Plasma Transfusion Dosing Algorithm in Patients With Chronic Liver Disease Unknown status NCT02366845 Phase 4
2 Branched-chain Amino Acid (BCAA) on Progression of Advanced Liver Disease Unknown status NCT02837302 Phase 4 Livact
3 Placebo Controlled Study Using Lovaza as Treatment for Non-Alcoholic Fatty Liver Disease Unknown status NCT00941642 Phase 4 Lovaza;placebo control
4 Perindopril and Telmisartan for the Treatment of Nonalcoholic Fatty Liver Disease Unknown status NCT02213224 Phase 4 Perindopril;Telmisartan;Amlodipine
5 The Effect Of Dual Treatment With L-Carnitine And Magnesium On Fatty Liver Unknown status NCT01956825 Phase 4
6 Exenatide Compared With Insulin Glargine to Change Liver Fat Content in Type 2 Diabetes Unknown status NCT02303730 Phase 4 Exenatide;insulin glargine
7 Efficacy and Safety of Ursodeoxycholic Acid (UDCA) Added to the DPP-4 Inhibitor in People With Type 2 Diabetes and Chronic Liver Diseases Unknown status NCT01337440 Phase 4 UDCA;Sitagliptin
8 Atorvastatin Versus Vitamin E in Treatment of Non-alcoholic Fatty Liver Disease Unknown status NCT01720719 Phase 4 atorvastatin;Vitamin E
9 Antiviral Therapy in Hepatitis B Virus (HBV)-Related Advanced Liver Disease Patients Unknown status NCT00823550 Phase 4 Entecavir;Lamivudine
10 Effect of Metadoxine on Oxidative Stress in Non-alcoholic Hepatic Steatosis Unknown status NCT02051842 Phase 4 Metadoxine
11 The Orange-III Trial: Optimised Recovery With Movicol® Preoperatively Within an Enhanced Recovery Programme Unknown status NCT01429779 Phase 4 Movicol
12 Intravenous-Morphine and Glucagon-Usage Enhanced MR Cholangiography Unknown status NCT00155376 Phase 4 morphine and glucagon
13 Effect of Probiotics on Gut-Liver Axis of Alcoholic Hepatitis Unknown status NCT02335632 Phase 4 Probiotics (Lacidofil®);Placebo
14 Emtricitabine for Naive Child Chinese Chronic Hepatitis B Patients Unknown status NCT02327676 Phase 4 Emtricitabine
15 Emtricitabine for Naive Chinese Chronic Hepatitis B Patients Unknown status NCT02327663 Phase 4 Emtricitabine
16 Treatment for Alcohol Dependence With Gabapentin Unknown status NCT02771925 Phase 4 Gabapentin 2g/day divided in two doses for 24 weeks;Placebo 2g/day divided in two doses for 24 weeks
17 RCT Study on Granulocyte Colony-stimulating Factor(G-CSF) Treatment of Hepatic Failure Unknown status NCT02331745 Phase 4 Granulocyte colony-stimulating factor;standard treatment
18 A Study of Thymoglobulin and Tacrolimus in Liver Transplant Unknown status NCT00564538 Phase 4 anti-thymocyte globulin (rabbit);tacrolimus
19 Lifestyle Versus Ezetimibe Plus Lifestyle in Patients With Non-alcoholic Steatohepatitis Unknown status NCT01950884 Phase 4 Ezetimibe
20 Emtricitabine for Prevention of Vertical Transmission of HBV in Chinese Pregnant HBsAg Positive Patients Unknown status NCT02327715 Phase 4 Emtricitabine
21 Emtricitabine for Naive Chinese Pregnant Chronic Hepatitis B Patients Unknown status NCT02327702 Phase 4 Emtricitabine
22 Emtricitabine Plus Adefovir Dipivoxil for Naive Chinese HBV Related Cirrhosis Patients Unknown status NCT02327689 Phase 4 Emtricitabine plus adefovir dipivoxil
23 Magnesium in Liver Cirrhosis Unknown status NCT01894867 Phase 4
24 Entecavir for Chronic Hepatitis B Patients With Persistently Normal ALT Unknown status NCT01833611 Phase 4 Entecavir;placebo
25 Telaprevir in Genotype 3 HCV Unknown status NCT02087111 Phase 4 Telaprevir;40 Kd Pegylated interferon alfa 2a;Ribavirin
26 Development of an Imaging Biomarker for Hepatic Fibrosis Using Gadoxetate Disodium Unknown status NCT01783314 Phase 4
27 Various Insulin Regimens for Diabetic Inpatients With Cirrhosis Trial Unknown status NCT01143948 Phase 4 Glargine & Glulisine;Regular insulin;NPH & regular insulin
28 Secondary Prophylaxis of Hepatic Encephalopathy in Cirrhosis Unknown status NCT01178372 Phase 4 Lactulose;Probiotics(VSL#3)
29 Pegylated-Interferon and Ribavirin Plus Metformin in the Treatment of Chronic HCV Infection and Insulin Resistance Unknown status NCT00370617 Phase 4 metformin
30 Effect of Liraglutide on Fatty Liver Content and Lipoprotein Metabolism Unknown status NCT02721888 Phase 4 Liraglutide;MRI/ MRS (Magnetic Resonance Imaging /Magnetic Resonance Spectroscopy)
31 Tenofovir Versus Tenofovir + Telbivudine for Chronic Hepatitis B Unknown status NCT02774837 Phase 4 Tenofovir disoproxil;Telbivudine
32 Efficacy of Telbivudine With or Without add-on Tenofovir According to Roadmap Strategy Compare With Entecavir Unknown status NCT01588912 Phase 4 Telbivudine;Tenofovir;Entecavir
33 Randomized Comparison of Two Albumin Administration Schedules for Spontaneous Bacterial Peritonitis (SBP) Unknown status NCT00761098 Phase 4 Standard Care;Experimental
34 Trial Comparing the Efficacy, Tolerability and Safety Between Three Arms in Treatment of HCV in Egyptian Population Unknown status NCT01896609 Phase 4 Bon one in Arm 3;Xerovirinc in Arm 2;Ribavirin in Arm 1
35 Efficacies of Entecavir Add on HBeAg Positive Patients With HBV DNA Positive During Peginterferon Alpha 2a Treatment Unknown status NCT02368288 Phase 4 entecavir
36 HIV Persistence and Viral Reservoirs Unknown status NCT01025427 Phase 4 Raltegravir, tenofovir/emtricitabine
37 Efficacies of Entecavir Add on HBeAg Negative Patients With HBV DNA Positive During Peginterferon Alpha 2a Treatment Unknown status NCT02365402 Phase 4 Entecavir
38 Efficacy of Peginterferon Alpha 2a Therapy in Chronic Hepatitis B Patients Being Treated With Nucleoside(Acid) Analogues Unknown status NCT02362490 Phase 4 peginterferon alpha 2a
39 Safety of Acamprosate for Alcohol Dependence in the Elderly: An Open-Label Study (SAFADIE) Unknown status NCT00655967 Phase 4 Acamprosate (Campral);Acamprosate
40 Rifaximin Versus Lactulose in Renal Failure Unknown status NCT00748904 Phase 4 Rifaximin;Lactulose
41 Erythromycin Treatment for Readthrough of APC Gene Stop Codon Mutations in Familial Adenomatous Polyposis Unknown status NCT02175914 Phase 4 Erythromycin
42 Influence of CYP3A5 Polymorphism on Liver Function Abnormality and the Trough Level Change After Conversion Unknown status NCT02882113 Phase 4 Advagraf
43 Crossover of Higher Dose Statins in Patients With Low High-density Lipoproteins Cholesterol (HDLc) Unknown status NCT00736463 Phase 4 Simvastatin;Atorvastatin 80 mg
44 Metformin for Weight Control in Adolescents Taking Atypical Antipsychotics Unknown status NCT00845936 Phase 4 Metformin
45 A Pilot Study to Treat Patients With Chronic Hepatitis C Virus (HCV) Genotype 1 and End-Stage Renal Disease (ESRD) Unknown status NCT01731301 Phase 4 Ribavirin;Peginterferon;Boceprevir
46 Assessment of Coagulation Abnormalities in Acute on Chronic Liver Failure Patients Using Thromboelastography Unknown status NCT02757170 Phase 4
47 Trial Comparing Metformin Versus Placebo in Non Alcoholic Steatohepatitis (NASH) Patients Receiving Bariatric Surgery for Obesity Unknown status NCT00134303 Phase 4 Metformin
48 Endoesophageal Cryotherapy For Ablating Barrett's Esophagus and Early Stage Esophageal Cancer Unknown status NCT00628784 Phase 4
49 Complex Imaging Assessment of Steatosis Unknown status NCT02669641 Phase 4
50 TO Compare the Triple Drug Therapy and Dual Therapy . Unknown status NCT02075242 Phase 4 Mycophenolate Mofetil;Tacrolimus

Search NIH Clinical Center for Liver Disease

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Liver Disease cell therapies at LifeMap Discovery.
Stem-cell-based therapeutic approaches for Liver Disease:
Adult stem cell therapy for liver insufficiency
Bone marrow-derived mesenchymal stem cells for treatment of liver failure
Embryonic/Adult Cultured Cells Related to Liver Disease:
Peripheral blood-derived hematopoietic stem cells PMIDs: 18181952 16556705 22121493
Bone marrow-derived mesenchymal stem cells (family)

Cochrane evidence based reviews: liver diseases

Sources

Genetic Tests for Liver Disease

About this section

Genetic tests related to Liver Disease:

# Genetic test Affiliating Genes
1 Hepatic Failure 29
2 Abnormality of the Liver 29
Sources

Anatomical Context for Liver Disease

About this section

MalaCards organs/tissues related to Liver Disease:

41
Liver, Testes, Kidney, Bone, Endothelial, Heart, T Cells
Sources

Publications for Liver Disease

About this section

Articles related to Liver Disease:

(show top 50) (show all 7939)
# Title Authors Year
1
Randomised clinical trial: emricasan versus placebo significantly decreases ALT and caspase 3/7 activation in subjects with non-alcoholic fatty liver disease. ( 30430605 )
2019
2
The Future of Nonalcoholic Fatty Liver Disease Treatment. ( 30466676 )
2019
3
Fatty liver disease: is it nonalcoholic fatty liver disease or obesity-associated fatty liver disease? ( 30507644 )
2019
4
Vitamin E alleviates non-alcoholic fatty liver disease in phosphatidylethanolamine N-methyltransferase deficient mice. ( 30300671 )
2019
5
Olive oil lessened fatty liver severity independent of cardiometabolic correction in patients with non-alcoholic fatty liver disease: A randomized clinical trial. ( 30170304 )
2019
6
Serum biomarkers of fibrosis and extracellular matrix remodeling in patients with nonalcoholic fatty liver disease: association with liver histology. ( 30134384 )
2019
7
Hepatoprotection by L-Ornithine L-Aspartate in Non-Alcoholic Fatty Liver Disease. ( 30016770 )
2019
8
The Pattern of Elevated Liver Function Tests in Nonalcoholic Fatty Liver Disease Predicts Fibrosis Stage and Metabolic-Associated Comorbidities. ( 30016799 )
2019
9
Progress and challenges in the prevention and control of nonalcoholic fatty liver disease. ( 29846945 )
2019
10
TLR3 and TLR4 SNP variants in the liver disease resulting from hepatitis B virus and hepatitis C virus infection. ( 30421643 )
2019
11
Circulating microRNAs as predictive biomarkers for liver disease progression of chronic hepatitis C (genotype-4) Egyptian patients. ( 30133717 )
2019
12
Caring for the Critically Ill Alcoholic Liver Disease Patient: An Uphill Battle Worth Fighting. ( 30557242 )
2019
13
Liver Transplantation for Alcoholic Liver Disease: An Update. ( 30454827 )
2019
14
Epidemiology of Alcohol Consumption and Societal Burden of Alcoholism and Alcoholic Liver Disease. ( 30454831 )
2019
15
Adolescent Alcoholic Liver Disease. ( 30454832 )
2019
16
Alcohol Use Disorders in Alcoholic Liver Disease. ( 30454833 )
2019
17
Pathogenesis of Alcoholic Liver Disease: An Update. ( 30454834 )
2019
18
Nutrition in Alcoholic Liver Disease: An Update. ( 30454836 )
2019
19
Alcohol and Alcoholic Liver Disease. ( 30454837 )
2019
20
Histopathology of Alcohol-Related Liver Diseases. ( 30454825 )
2019
21
The Functions of Selenium and Selenoproteins Relating to the Liver Diseases. ( 30486929 )
2019
22
Thrombopoietin receptor agonists and risk of portal vein thrombosis in patients with liver disease and thrombocytopenia: A meta-analysis. ( 29958825 )
2018
23
Obestatin protects and reverses nonalcoholic fatty liver disease and its associated insulin resistance in rats via inhibition of food intake, enhancing hepatic adiponectin signaling, and blocking ghrelin acylation. ( 29429367 )
2018
24
Impact of liver volume on polycystic liver disease-related symptoms and quality of life. ( 29435317 )
2018
25
Simultaneous quantification of hepatic MRI-PDFF and R2* in a rabbit model with nonalcoholic fatty liver disease. ( 29934919 )
2018
26
Chicory (Cichorium intybus L.) polysaccharides attenuate high-fat diet induced non-alcoholic fatty liver disease via AMPK activation. ( 29964102 )
2018
27
Taurine attenuates the development of hepatic steatosis through the inhibition of oxidative stress in a model of nonalcoholic fatty liver disease in vivo and in vitro. ( 29946793 )
2018
28
Nonalcoholic Fatty Liver Disease: Time to Take the Bull by the Horns. ( 29963461 )
2018
29
Role of genetic and metabolism in non-alcoholic fatty liver disease. ( 29442484 )
2018
30
Effects of isomaltulose on insulin resistance and metabolites in patients with nona89alcoholic fatty liver disease: A metabolomic analysis. ( 29956790 )
2018
31
Noninvasive Quantitative Detection Methods of Liver Fat Content in Nonalcoholic Fatty Liver Disease. ( 29951367 )
2018
32
PNPLA3: A Determinant of Response to Low-Fructose Diet in Nonalcoholic Fatty Liver Disease. ( 29452087 )
2018
33
Quantification of hepatic perfusion and hepatocyte function with dynamic gadoxetic acid-enhanced MR imaging in patients with chronic liver disease. ( 29440620 )
2018
34
Multiparametric MRI for early detection of diffuse liver disease: an interview with David Breen. ( 29318905 )
2018
35
A Case-control Study to Evaluate the Prevalence of Nonalcoholic Fatty Liver Disease Among Patients with Moderate-to-severe Psoriasis. ( 29942422 )
2018
36
Dysbiosis of oral microbiota and its association with salivary immunological biomarkers in autoimmune liver disease. ( 29969462 )
2018
37
Role of palliative resection of the primary pancreatic neuroendocrine tumor in patients with unresectable metastatic liver disease: a systematic review and meta-analysis. ( 29503572 )
2018
38
Exploring the relationship between nonalcoholic fatty liver disease and pancreatic cancer by computed tomographic survey. ( 29235054 )
2018
39
Editorial: the role of colonic inflammation in the progression of liver disease in primary sclerosing cholangitis-Authors' reply and Letter: the effects of colectomy prior to the diagnosis of primary sclerosing cholangitis on prognosis may have been overestimated. ( 29314129 )
2018
40
Model for end-stage liver disease predicts mortality after pericardiectomy for constrictive pericarditis. ( 29893857 )
2018
41
Statin Use In Cirrhosis from Fatty Liver Disease. ( 29443384 )
2018
42
Liver disease in patients with cystic fibrosis. ( 29438119 )
2018
43
Urea cycle dysregulation in non-alcoholic fatty liver disease. ( 29981428 )
2018
44
Unexplained chronic liver disease in Ethiopia: a cross-sectional study. ( 29439653 )
2018
45
THE USE OF MELD SCORE (MODEL FOR END-STAGE LIVER DISEASE) AND DERIVATIVES IN CARDIAC TRANSPLANTATION. ( 29972398 )
2018
46
Open-label study of ademetionine for the treatment of intrahepatic cholestasis associated with alcoholic liver disease. ( 29431335 )
2018
47
Practical Dietary Recommendations for the Prevention and Management of Nonalcoholic Fatty Liver Disease in Adults. ( 29438460 )
2018
48
Presentation and prognosis of liver disease in alpha-1 antitrypsin deficiency. ( 29768056 )
2018
49
Diagnosis of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis: Why liver biopsy is essential. ( 29427497 )
2018
50
Noninvasive Assessment of Portal Hypertension in Advanced Chronic Liver Disease: An Update. ( 29977287 )
2018
Sources

Variations for Liver Disease

About this section
Sources

Expression for Liver Disease

About this section
Search GEO for disease gene expression data for Liver Disease.
Sources

Pathways for Liver Disease

About this section

Pathways related to Liver Disease according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Metabolism 66
Show member pathways
 13.67 ABCB11 ABCB4 ADIPOQ ALB CYP2E1 DLAT
2
Selenium Micronutrient Network 1
Show member pathways
 11.96 ALB F2 INS TNF
3
Type II diabetes mellitus 37 1
Show member pathways
 11.53 ADIPOQ INS TNF
4
Adipogenesis 1
11.38 ADIPOQ INS PNPLA3 TNF
5
FOXA2 and FOXA3 transcription factor networks 1
10.98 ALB F2 INS
6
Farnesoid X Receptor Pathway 1
10.71 ABCB11 ABCB4
7
Cori Cycle 1
10.61 GPT INS
8
Nuclear Receptors in Lipid Metabolism and Toxicity 1
10.34 ABCB11 ABCB4 CYP2E1
Sources

GO Terms for Liver Disease

About this section

Cellular components related to Liver Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 endoplasmic reticulum GO:0005783 9.87 ADIPOQ ALB CYP2E1 GANAB HSD3B7 PRKCSH
2 extracellular exosome GO:0070062 9.7 ABCB11 ABCB4 ALB F2 FAH GANAB
3 intercellular canaliculus GO:0046581 9.26 ABCB11 ABCB4
4 glucosidase II complex GO:0017177 9.16 GANAB PRKCSH
5 endoplasmic reticulum lumen GO:0005788 9.1 ALB F2 GANAB INS PRKCSH SERPINA1

Biological processes related to Liver Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 nitrogen compound metabolic process GO:0006807 9.48 PKD1 PRKCSH
2 negative regulation of lipid catabolic process GO:0050995 9.46 INS TNF
3 positive regulation of cellular protein metabolic process GO:0032270 9.43 ADIPOQ INS
4 positive regulation of phosphatidylinositol 3-kinase signaling GO:0014068 9.43 F2 INS TNF
5 negative regulation of gluconeogenesis GO:0045721 9.4 ADIPOQ INS
6 N-glycan processing GO:0006491 9.37 GANAB PRKCSH
7 cellular protein metabolic process GO:0044267 9.35 ALB F2 INS PRKCSH SERPINA1
8 acute-phase response GO:0006953 9.33 F2 INS SERPINA1
9 regulation of protein secretion GO:0050708 9.32 INS TNF
10 glucose metabolic process GO:0006006 8.92 ADIPOQ DLAT INS TNF

Molecular functions related to Liver Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protease binding GO:0002020 8.8 INS SERPINA1 TNF
Sources

Sources for Liver Disease

About this section
3 CDC
4